<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:55:31Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5759817" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:5759817</identifier>
        <datestamp>2018-07-01</datestamp>
        <setSpec>oncologist</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Oncologist</journal-id>
              <journal-id journal-id-type="iso-abbrev">Oncologist</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)1549-490X</journal-id>
              <journal-id journal-id-type="publisher-id">The Oncologist</journal-id>
              <journal-id journal-id-type="pmc">oncologist</journal-id>
              <journal-id journal-id-type="hwp">theoncologist</journal-id>
              <journal-title-group>
                <journal-title>The Oncologist</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1083-7159</issn>
              <issn pub-type="epub">1549-490X</issn>
              <publisher>
                <publisher-name>AlphaMed Press</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC5759817</article-id>
              <article-id pub-id-type="pmcid">PMC5759817</article-id>
              <article-id pub-id-type="pmc-uid">5759817</article-id>
              <article-id pub-id-type="pmid">28935775</article-id>
              <article-id pub-id-type="doi">10.1634/theoncologist.2017-0255</article-id>
              <article-id pub-id-type="publisher-id">ONCO12255</article-id>
              <article-categories>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>26</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Symptom Management and Supportive Care</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Sarcopenia Is Associated with Quality of Life and Depression in Patients with Advanced Cancer</article-title>
              </title-group>
              <contrib-group>
                <contrib id="onco12255-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Nipp</surname>
                    <given-names>Ryan D.</given-names>
                  </name>
                  <address>
                    <email>RNipp@MGH.Harvard.edu</email>
                  </address>
                  <xref ref-type="correspondence-address" rid="correspondenceTo">*</xref>
                  <xref ref-type="aff" rid="onco12255-aff-0001">
                    <sup>a</sup>
                  </xref>
                  <xref ref-type="fn" rid="onco12255-note-0001">
                    <sup>†</sup>
                  </xref>
                </contrib>
                <contrib id="onco12255-cr-0002" contrib-type="author">
                  <name>
                    <surname>Fuchs</surname>
                    <given-names>Georg</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12255-aff-0002">
                    <sup>b</sup>
                  </xref>
                  <xref ref-type="fn" rid="onco12255-note-0001">
                    <sup>†</sup>
                  </xref>
                </contrib>
                <contrib id="onco12255-cr-0003" contrib-type="author">
                  <name>
                    <surname>El‐Jawahri</surname>
                    <given-names>Areej</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12255-aff-0001">
                    <sup>a</sup>
                  </xref>
                </contrib>
                <contrib id="onco12255-cr-0004" contrib-type="author">
                  <name>
                    <surname>Mario</surname>
                    <given-names>Julia</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12255-aff-0003">
                    <sup>c</sup>
                  </xref>
                </contrib>
                <contrib id="onco12255-cr-0005" contrib-type="author">
                  <name>
                    <surname>Troschel</surname>
                    <given-names>Fabian M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12255-aff-0003">
                    <sup>c</sup>
                  </xref>
                </contrib>
                <contrib id="onco12255-cr-0006" contrib-type="author">
                  <name>
                    <surname>Greer</surname>
                    <given-names>Joseph A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12255-aff-0004">
                    <sup>d</sup>
                  </xref>
                </contrib>
                <contrib id="onco12255-cr-0007" contrib-type="author">
                  <name>
                    <surname>Gallagher</surname>
                    <given-names>Emily R.</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12255-aff-0001">
                    <sup>a</sup>
                  </xref>
                </contrib>
                <contrib id="onco12255-cr-0008" contrib-type="author">
                  <name>
                    <surname>Jackson</surname>
                    <given-names>Vicki A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12255-aff-0005">
                    <sup>e</sup>
                  </xref>
                </contrib>
                <contrib id="onco12255-cr-0009" contrib-type="author">
                  <name>
                    <surname>Kambadakone</surname>
                    <given-names>Avinash</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12255-aff-0003">
                    <sup>c</sup>
                  </xref>
                </contrib>
                <contrib id="onco12255-cr-00010" contrib-type="author">
                  <name>
                    <surname>Hong</surname>
                    <given-names>Theodore S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12255-aff-0006">
                    <sup>f</sup>
                  </xref>
                </contrib>
                <contrib id="onco12255-cr-00011" contrib-type="author">
                  <name>
                    <surname>Temel</surname>
                    <given-names>Jennifer S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12255-aff-0001">
                    <sup>a</sup>
                  </xref>
                  <xref ref-type="fn" rid="onco12255-note-0002">
                    <sup>‡</sup>
                  </xref>
                </contrib>
                <contrib id="onco12255-cr-00012" contrib-type="author">
                  <name>
                    <surname>Fintelmann</surname>
                    <given-names>Florian J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12255-aff-0003">
                    <sup>c</sup>
                  </xref>
                  <xref ref-type="fn" rid="onco12255-note-0002">
                    <sup>‡</sup>
                  </xref>
                </contrib>
                <aff id="onco12255-aff-0001"><label><sup>a</sup></label><institution>Department of Medicine, Division of Hematology &amp; Oncology, Massachusetts General Hospital Cancer Center &amp; Harvard Medical School</institution>, <city>Boston</city>, <state>Massachusetts</state>, <country>USA</country></aff>
                <aff id="onco12255-aff-0002"><label><sup>b</sup></label><institution>Department of Radiology, Charité ‐ Universitätsmedizin Berlin</institution>, <city>Berlin</city>, <country country="DE">Germany</country></aff>
                <aff id="onco12255-aff-0003"><label><sup>c</sup></label><institution>Department of Radiology, Massachusetts General Hospital &amp; Harvard Medical School</institution>, <city>Boston</city>, <state>Massachusetts</state>, <country>USA</country></aff>
                <aff id="onco12255-aff-0004"><label><sup>d</sup></label><institution>Department of Psychiatry, Massachusetts General Hospital &amp; Harvard Medical School</institution>, <city>Boston</city>, <state>Massachusetts</state>, <country country="US">USA</country></aff>
                <aff id="onco12255-aff-0005"><label><sup>e</sup></label><institution>Department of Medicine, Division of Palliative Care, Massachusetts General Hospital &amp; Harvard Medical School</institution>, <city>Boston</city>, <state>Massachusetts</state>, <country country="US">USA</country></aff>
                <aff id="onco12255-aff-0006"><label><sup>f</sup></label><institution>Department of Radiation Oncology, Division of Hematology &amp; Oncology, Massachusetts General Hospital Cancer Center &amp; Harvard Medical School</institution>, <city>Boston</city>, <state>Massachusetts</state>, <country country="US">USA</country></aff>
              </contrib-group>
              <author-notes>
                <fn id="onco12255-note-0003" fn-type="COI-statement">
                  <p><italic>Disclosures of potential conflicts of interest may be found at the end of this article</italic>.</p>
                </fn>
                <corresp id="correspondenceTo"><label>*</label>Correspondence: Ryan Nipp, M.D., M.P.H., Department of Medicine, Division of Hematology &amp; Oncology, Massachusetts General Hospital Cancer Center &amp; Harvard Medical School, 55 Fruit Street, Boston, Massachusetts 02114, USA. Telephone: 617‐724‐4000; e‐mail: <email>RNipp@MGH.Harvard.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>21</day>
                <month>9</month>
                <year>2017</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>1</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>1</day>
                <month>7</month>
                <year>2018</year>
              </pub-date>
              <!-- PMC Release delay is 6 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
              <volume>23</volume>
              <issue>1</issue>
              <issue-id pub-id-type="doi">10.1002/onco.v23.1</issue-id>
              <fpage>97</fpage>
              <lpage>104</lpage>
              <history>
                <date date-type="received">
                  <day>30</day>
                  <month>5</month>
                  <year>2017</year>
                </date>
                <date date-type="accepted">
                  <day>22</day>
                  <month>8</month>
                  <year>2017</year>
                </date>
              </history>
              <permissions>
                <copyright-statement content-type="article-copyright">© AlphaMed Press 2017</copyright-statement>
              </permissions>
              <self-uri content-type="pdf" xlink:href="onco12255.pdf"/>
              <abstract abstract-type="precis">
                <p>Cancer cachexia and sarcopenia can occur frequently in patients with advanced cancer, and may negatively affect treatment outcomes. This article highlights the importance of assessing sarcopenia and describes the relationship between sarcopenia and patients' quality of life in patients with newly diagnosed, incurable cancer.</p>
              </abstract>
              <abstract>
                <title>Abstract</title>
                <sec id="onco12255-sec-0001">
                  <title>Background.</title>
                  <p>Patients with advanced cancer often experience muscle wasting (sarcopenia), yet little is known about the characteristics associated with sarcopenia and the relationship between sarcopenia and patients’ quality of life (QOL) and mood.</p>
                </sec>
                <sec id="onco12255-sec-0002">
                  <title>Materials and Methods.</title>
                  <p>As part of a randomized trial, we assessed baseline QOL (Functional Assessment of Cancer Therapy‐General [FACT‐G]) and mood (Hospital Anxiety and Depression Scale [HADS]) in patients within 8 weeks of diagnosis of incurable lung or gastrointestinal cancer, and prior to randomization. Using computed tomography scans collected as part of routine clinical care, we assessed sarcopenia at the level of the third lumbar vertebra with validated sex‐specific cutoffs. We used logistic regression to explore characteristics associated with presence of sarcopenia. To examine associations between sarcopenia, QOL and mood, we used linear regression, adjusted for patients’ age, sex, marital status, education, and cancer type.</p>
                </sec>
                <sec id="onco12255-sec-0003">
                  <title>Results.</title>
                  <p>Of 237 participants (mean age = 64.41 ± 10.93 years), the majority were male (54.0%) and married (70.5%) and had lung cancer (56.5%). Over half had sarcopenia (55.3%). Older age (odds ratio [OR] = 1.05, <italic>p</italic> = .002) and education beyond high school (OR = 1.95, <italic>p</italic> = .047) were associated with greater likelihood of having sarcopenia, while female sex (OR = 0.25, <italic>p</italic> &lt; .001) and higher body mass index (OR = 0.79, <italic>p</italic> &lt; .001) correlated with lower likelihood of sarcopenia. Sarcopenia was associated with worse QOL (FACT‐G: B = −4.26, <italic>p</italic> = .048) and greater depression symptoms (HADS‐depression: B = −1.56, <italic>p</italic> = .005).</p>
                </sec>
                <sec id="onco12255-sec-0004">
                  <title>Conclusion.</title>
                  <p>Sarcopenia was highly prevalent among patients with newly diagnosed, incurable cancer. The associations of sarcopenia with worse QOL and depression symptoms highlight the need to address the issue of sarcopenia early in the course of illness.</p>
                </sec>
                <sec id="onco12255-sec-1005">
                  <title>Implications for Practice.</title>
                  <p>This study found that sarcopenia, assessed using computed tomography scans acquired as part of routine clinical care, is highly prevalent in patients with newly diagnosed, incurable cancer. Notably, patients with sarcopenia reported worse quality of life and greater depression symptoms than those without sarcopenia. These findings highlight the importance of addressing muscle loss early in the course of illness among patients with incurable cancer. In the future, investigators should expand upon these findings to develop strategies for assessing and treating sarcopenia while striving to enhance the quality of life and mood outcomes of patients with advanced cancer.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="onco12255-kwd-0001">Sarcopenia</kwd>
                <kwd id="onco12255-kwd-0002">Depression</kwd>
                <kwd id="onco12255-kwd-0003">Quality of life</kwd>
                <kwd id="onco12255-kwd-0004">Advanced cancer</kwd>
                <kwd id="onco12255-kwd-0005">Palliative care</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Institute of Nursing Research
</institution>
                      <institution-id>http://dx.doi.org/10.13039/100000056</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>R01 NR012735
</award-id>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Cancer Institute
</institution>
                      <institution-id>http://dx.doi.org/10.13039/100000054</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>K24 CA181253
</award-id>
                </award-group>
              </funding-group>
              <counts>
                <page-count count="8"/>
              </counts>
            </article-meta>
            <notes>
              <fn-group>
                <fn id="onco12255-note-0001" fn-type="equal">
                  <label>†</label>
                  <p>Contributed equally as co‐first authors</p>
                </fn>
                <fn id="onco12255-note-0002" fn-type="equal">
                  <label>‡</label>
                  <p>Contributed equally as co‐senior authors</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body>
            <sec id="onco12255-sec-0005">
              <title>Introduction</title>
              <p>Cancer cachexia, a syndrome of weight loss and low muscle mass (sarcopenia), occurs frequently in patients with advanced cancer and can negatively impact their outcomes, including treatment tolerance and survival [<xref rid="onco12255-bib-0001" ref-type="ref">1</xref>], [<xref rid="onco12255-bib-0002" ref-type="ref">2</xref>], [<xref rid="onco12255-bib-0003" ref-type="ref">3</xref>], [<xref rid="onco12255-bib-0004" ref-type="ref">4</xref>], [<xref rid="onco12255-bib-0005" ref-type="ref">5</xref>], [<xref rid="onco12255-bib-0006" ref-type="ref">6</xref>]. Causes of cancer cachexia include reduced food intake, diminished physical activity, and abnormal metabolism [<xref rid="onco12255-bib-0007" ref-type="ref">7</xref>], [<xref rid="onco12255-bib-0008" ref-type="ref">8</xref>], [<xref rid="onco12255-bib-0009" ref-type="ref">9</xref>]. Data suggest that patients with cancer cachexia experience poor treatment tolerance and worse morbidity and mortality compared with patients who maintain their weight and muscle mass [<xref rid="onco12255-bib-0001" ref-type="ref">1</xref>], [<xref rid="onco12255-bib-0002" ref-type="ref">2</xref>], [<xref rid="onco12255-bib-0003" ref-type="ref">3</xref>], [<xref rid="onco12255-bib-0004" ref-type="ref">4</xref>], [<xref rid="onco12255-bib-0005" ref-type="ref">5</xref>], [<xref rid="onco12255-bib-0006" ref-type="ref">6</xref>]. In addition, cachexia has been linked to worse physical function and loss of functional independence [<xref rid="onco12255-bib-0006" ref-type="ref">6</xref>], [<xref rid="onco12255-bib-0010" ref-type="ref">10</xref>], [<xref rid="onco12255-bib-0011" ref-type="ref">11</xref>]. Thus, cancer cachexia is a common and detrimental problem for patients with cancer, yet it often goes unaddressed and has been understudied among patients with advanced cancer [<xref rid="onco12255-bib-0012" ref-type="ref">12</xref>].</p>
              <p>Previous studies addressing cancer cachexia have been limited by the lack of a standard definition [<xref rid="onco12255-bib-0013" ref-type="ref">13</xref>]. Cachexia, sarcopenia, and solitary muscle loss represent different aspects of the muscle wasting spectrum and can have different clinical presentations and prognoses [<xref rid="onco12255-bib-0014" ref-type="ref">14</xref>], [<xref rid="onco12255-bib-0015" ref-type="ref">15</xref>]. Simply measuring body weight to quantify cachexia is not adequate, as this fails to account for fluid accumulation, large tumor burden, and the slow rate of visceral organ atrophy present in some patients with cancer [<xref rid="onco12255-bib-0016" ref-type="ref">16</xref>], [<xref rid="onco12255-bib-0017" ref-type="ref">17</xref>]. Loss of muscle mass occurs frequently in patients with advanced cancer, though clinicians are often unaware of their patients’ muscle mass by assessing body weight alone [<xref rid="onco12255-bib-0006" ref-type="ref">6</xref>], [<xref rid="onco12255-bib-0018" ref-type="ref">18</xref>]. Recently, an international consensus panel published a report clarifying the definition and classification of cancer cachexia [<xref rid="onco12255-bib-0015" ref-type="ref">15</xref>]. This report highlighted the importance of assessing sarcopenia, defined by quantifying muscle mass using routinely collected computed tomography (CT), among patients with cancer. As a result, investigators studying cancer cachexia frequently use patients’ CT scans to assess sarcopenia. However, we lack data regarding the relationship between these CT scan measurements of sarcopenia and important patient‐reported outcomes, such as quality of life (QOL) and mood among patients with advanced cancer.</p>
              <p>Understanding the association between sarcopenia and patients’ QOL and mood is particularly important for patients with advanced cancer, as efforts to improve these outcomes are essential components of caring for this population. Notably, patients with advanced cancer are more likely to suffer the consequences of sarcopenia than those with curable disease, as they often experience a high symptom burden, including nausea, poor appetite, and fatigue [<xref rid="onco12255-bib-0019" ref-type="ref">19</xref>], [<xref rid="onco12255-bib-0020" ref-type="ref">20</xref>]. Additionally, sarcopenia can negatively affect patients’ functional status and independence [<xref rid="onco12255-bib-0006" ref-type="ref">6</xref>], [<xref rid="onco12255-bib-0010" ref-type="ref">10</xref>], [<xref rid="onco12255-bib-0011" ref-type="ref">11</xref>], which may influence both their physical and emotional well‐being. Importantly, the manifestations of sarcopenia often appear gradually, as the disease worsens, and clinicians may only discover the profound muscle loss late in the disease trajectory, when efforts to intervene are less likely to provide much benefit. Thus, studies are needed to define the prevalence and understand the impact of sarcopenia earlier in the disease course, at a time when patients may experience the benefits of interventions focused on maintaining and improving their muscle mass.</p>
              <p>Using baseline data from a randomized trial, we sought to explore the relationships among sarcopenia (using consensus definitions that recommend assessing muscle mass with CT scans [<xref rid="onco12255-bib-0015" ref-type="ref">15</xref>]), QOL, and mood in patients with newly diagnosed, incurable cancer. We hypothesized that a substantial proportion of patients would meet criteria for sarcopenia on CT scans, even at an early point in the disease trajectory, and these patients would report worse QOL and mood symptoms compared with those without sarcopenia. By studying the relationship between sarcopenia and patients’ QOL and mood, this study will inform future interventions seeking to address sarcopenia earlier in the disease course among patients with newly diagnosed, incurable cancer, ideally to improve their experience with the illness and health outcomes.</p>
            </sec>
            <sec id="onco12255-sec-0006">
              <title>Materials and Methods</title>
              <sec id="onco12255-sec-0007">
                <title>Study Design</title>
                <p>As part of a randomized trial of early palliative care integrated with oncology care versus oncology care alone [<xref rid="onco12255-bib-0021" ref-type="ref">21</xref>], we approached patients within 8 weeks of diagnosis with incurable cancer. For the current study, we utilized patient‐reported data collected at baseline after informed consent, but prior to patient randomization and the start of the intervention. The Dana‐Farber/Harvard Cancer Care Institutional Review Board approved the study protocol.</p>
              </sec>
              <sec id="onco12255-sec-0008">
                <title>Patient Selection</title>
                <p>The study sample was comprised of patients from Massachusetts General Hospital (MGH) Cancer Center with a confirmed diagnosis of incurable lung or noncolorectal gastrointestinal cancer within the previous 8 weeks and no prior therapy for metastatic disease. Other patient eligibility criteria included not receiving treatment with curative intent, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, age ≥18 years, plan to receive cancer care at MGH, and the ability to read and respond to questions in English or with minimal assistance from family or an interpreter. We did not enroll patients who were already receiving palliative care services, needed immediate referral for palliative care or hospice, or had significant psychiatric or other comorbid disease that would interfere with informed consent or study participation.</p>
              </sec>
              <sec id="onco12255-sec-0009">
                <title>Study Measures</title>
                <sec id="onco12255-sec-0010">
                  <title>Sociodemographic and Clinical Factors.</title>
                  <p>Participants completed a demographic questionnaire that included race, ethnicity, smoking history, religion, relationship status, education, and income. We reviewed participants’ electronic medical records to obtain data on their age, sex, cancer diagnosis, ECOG performance status, and initial cancer treatment.</p>
                </sec>
                <sec id="onco12255-sec-0011">
                  <title>Quality of Life.</title>
                  <p>We measured participants’ QOL using the Functional Assessment of Cancer Therapy‐General (FACT‐G) [<xref rid="onco12255-bib-0022" ref-type="ref">22</xref>]. The FACT‐G contains 27 items with subscales assessing well‐being across four domains (physical, functional, emotional, and social) during the past week. Higher scores indicate better QOL.</p>
                </sec>
                <sec id="onco12255-sec-0012">
                  <title>Depression and Anxiety.</title>
                  <p>We measured patients’ depression and anxiety symptoms using the Hospital Anxiety and Depression Scale (HADS) [<xref rid="onco12255-bib-0023" ref-type="ref">23</xref>]. The 14‐item HADS contains two 7‐item subscales assessing depression and anxiety symptoms during the past week. Higher total and subscale scores indicate worse symptoms, and a score greater than 7 denotes clinically significant depression or anxiety.</p>
                </sec>
                <sec id="onco12255-sec-0013">
                  <title>Sarcopenia Measured on CT Scans.</title>
                  <p>We assessed for the presence of sarcopenia using CT scans collected as part of routine clinical care. We limited our study sample to only those patients with CT scans within 30 days before or after their baseline questionnaires and utilized only the CT scan closest to the date of the baseline questionnaire. We quantified skeletal muscle cross‐sectional area (CSA) in cm<sup>2</sup> on a single axial image at the level of the third lumbar (L3) vertebral body with semi‐automated threshold‐based segmentation (OsiriX; Pixmeo, Bernex, Switzerland, <ext-link ext-link-type="uri" xlink:href="http://www.osirix-viewer.com">http://www.osirix-viewer.com</ext-link>/). We used attenuation thresholds set at −29 and +150 Hounsfield units for skeletal muscle [<xref rid="onco12255-bib-0024" ref-type="ref">24</xref>]. Figure <xref rid="onco12255-fig-0001" ref-type="fig">1</xref> displays examples of patients with high and low muscle mass using our technique. We computed the lean muscle CSA in cm<sup>2</sup> by summing the given tissue's pixels and multiplying the sum by the absolute unit pixel surface area. A research assistant (G.F.) performed the measurement, and a board‐certified radiologist (F.J.F.) with 8 years of experience verified each analysis. To assess inter‐ and intra‐analyst agreement, we randomly selected 40 images and then had these images re‐analyzed independently 9 months later by a second research assistant (J.M.) and by the primary analyst. We achieved excellent inter‐ and intra‐analyst agreement with intraclass correlation coefficients of 0.9965 and 0.9996, respectively. We normalized skeletal muscle CSA for stature and reported this skeletal muscle index as cm<sup>2</sup>/m<sup>2</sup>. For the current study, we defined sarcopenia as an L3 skeletal muscle index of &lt;55 cm<sup>2</sup>/m<sup>2</sup> for men and &lt;39 cm<sup>2</sup>/m<sup>2</sup> for women, as proposed by the international consensus for cancer cachexia [<xref rid="onco12255-bib-0015" ref-type="ref">15</xref>].</p>
                  <fig fig-type="Figure" xml:lang="en" id="onco12255-fig-0001" orientation="portrait" position="float">
                    <label>Figure 1.</label>
                    <caption>
                      <p>Computed tomography (CT) scans demonstrating patients with high (90th percentile) and low (10th percentile) muscle mass. Axial CT images of the third lumbar vertebra region, with skeletal muscle highlighted in red. <bold>(A)</bold>: Image of a 61‐year‐old female patient with skeletal muscle index of 34.2 cm<sup>2</sup>/m<sup>2</sup>. <bold>(B)</bold>: Image of a 53‐year‐old male patient with skeletal muscle index of 60.4 cm<sup>2</sup>/m<sup>2</sup>.</p>
                    </caption>
                    <graphic id="nlm-graphic-1" specific-use="sourcefile-name" xlink:href="onco12255-fig-0001">
                      <alt-text>image</alt-text>
                    </graphic>
                  </fig>
                </sec>
              </sec>
              <sec id="onco12255-sec-0014">
                <title>Statistical Analysis</title>
                <p>We used descriptive statistics to analyze the frequencies, medians, means, and standard deviations (SDs) of the study variables for the overall study sample. We compared baseline characteristics of participants with and without sarcopenia using chi‐square or Fisher's exact test for the categorical variables and independent‐samples Student's <italic>t</italic> tests for the continuous variables. We used logistic regression, adjusted for variables with <italic>p</italic> &lt; .25 on univariate analysis, to explore patient characteristics independently associated with the presence of sarcopenia. To examine the associations between sarcopenia (independent variable of interest) and patients’ QOL and mood (dependent variables), we computed linear regression models adjusting for potential confounders, including age, sex, marital status, education, and cancer type [<xref rid="onco12255-bib-0025" ref-type="ref">25</xref>], [<xref rid="onco12255-bib-0026" ref-type="ref">26</xref>]. We performed our statistical analyses using SPSS version 17.0 (IBM, Armonk, NY, <ext-link ext-link-type="uri" xlink:href="http://www.ibm.com">www.ibm.com</ext-link>).</p>
              </sec>
            </sec>
            <sec id="onco12255-sec-0015">
              <title>Results</title>
              <sec id="onco12255-sec-0016">
                <title>Participant Sample</title>
                <p>From May 2011 to July 2015, we enrolled 350 of 480 (72.9%) eligible patients, and for the current study we included 237 participants who had evaluable baseline CT scans. We compared participant characteristics between those with and without evaluable CT scans and found that these groups only differed across religion and not any other characteristic (<ext-link ext-link-type="uri" xlink:href="http://theoncologist.alphamedpress.org/lookup/suppl/doi:10.1634/theoncologist.2017-0255/-/DC2">supplemental online Table 1</ext-link>). Sample characteristics are presented in Table <xref rid="onco12255-tbl-0001" ref-type="table">1</xref>. Participants (mean age, 64.41 ± SD 10.93 years) were primarily white (93.2%), and the majority were male (54.0%) and married (70.5%) and had a lung cancer diagnosis (56.5%).</p>
                <table-wrap id="onco12255-tbl-0001" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 1.</label>
                  <caption>
                    <title>Baseline characteristics of study participants</title>
                  </caption>
                  <graphic id="nlm-graphic-5" specific-use="sourcefile-name" xlink:href="onco12255-tbl-0001">
                    <alt-text>image</alt-text>
                    <permissions>
                      <copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder>
                    </permissions>
                  </graphic>
                  <table-wrap-foot>
                    <fn id="onco12255-note-0005">
                      <label>a</label>
                      <p>One person who received transarterial chemoembolization (TACE) as their initial cancer therapy is included within the radiation category.</p>
                    </fn>
                    <fn id="onco12255-note-0006">
                      <label>b</label>
                      <p><italic>p</italic>‐value for married versus not married.</p>
                    </fn>
                    <fn id="onco12255-note-0007">
                      <p>Abbreviations: BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; SD, standard deviation.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="onco12255-sec-0017">
                <title>Sarcopenia</title>
                <p>Over half (55.3%) of patients had sarcopenia (<ext-link ext-link-type="uri" xlink:href="http://theoncologist.alphamedpress.org/lookup/suppl/doi:10.1634/theoncologist.2017-0255/-/DC1">supplemental online Fig. 1</ext-link>). Patients with sarcopenia were older (66.66 years vs. 61.63 years, <italic>p</italic> &lt; .001) and more likely to be male (65.6% vs. 39.6%, <italic>p</italic> &lt; .001), of non‐Hispanic ethnicity (0.0% vs. 6.6%, <italic>p</italic> = .003), and educated beyond high school (67.9% vs. 50.9%, <italic>p</italic> = .011). Multivariable logistic regression analyses showed that older age (odds ratio [OR] = 1.05, <italic>p</italic> = .002), white race (OR = 5.03, <italic>p</italic> = .02), and education beyond high school (OR = 1.95, <italic>p</italic> = .047) were associated with higher likelihood of sarcopenia, whereas female sex (OR = 0.25, <italic>p</italic> &lt; .001) and higher body mass index (BMI; OR = 0.79, <italic>p</italic> &lt; .001) were associated with lower likelihood of sarcopenia (Table <xref rid="onco12255-tbl-0002" ref-type="table">2</xref>).</p>
                <table-wrap id="onco12255-tbl-0002" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 2.</label>
                  <caption>
                    <title>Associations between patient characteristics and sarcopenia</title>
                  </caption>
                  <graphic id="nlm-graphic-7" specific-use="sourcefile-name" xlink:href="onco12255-tbl-0002">
                    <alt-text>image</alt-text>
                    <permissions>
                      <copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder>
                    </permissions>
                  </graphic>
                  <table-wrap-foot>
                    <fn id="onco12255-note-0008">
                      <label>a</label>
                      <p>Included variables with <italic>p</italic> &lt; .25 on univariate analysis.</p>
                    </fn>
                    <fn id="onco12255-note-0009">
                      <p>Abbreviations: BMI, body mass index; CI, confidence interval; OR, odds ratio; SE, standard error.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="onco12255-sec-0018">
                <title>Associations Between Sarcopenia and Patient‐Reported Measures</title>
                <p>Using linear regression adjusting for patients’ age, sex, marital status, education, and cancer type, we found that sarcopenia was associated with worse QOL (Table <xref rid="onco12255-tbl-0003" ref-type="table">3</xref>). Specifically, sarcopenia was associated with lower FACT‐G scores (unstandardized coefficient [B] = −4.26, standard error [SE] = 2.15, 95% confidence interval [CI] = −8.49 to −0.03, <italic>p</italic> = .048).</p>
                <table-wrap id="onco12255-tbl-0003" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 3.</label>
                  <caption>
                    <title>Associations between sarcopenia and patient‐reported outcomes</title>
                  </caption>
                  <graphic id="nlm-graphic-9" specific-use="sourcefile-name" xlink:href="onco12255-tbl-0003">
                    <alt-text>image</alt-text>
                    <permissions>
                      <copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder>
                    </permissions>
                  </graphic>
                  <table-wrap-foot>
                    <fn id="onco12255-note-0010">
                      <label>a</label>
                      <p>Adjusted for age, sex, marital status, education, and cancer type.</p>
                    </fn>
                    <fn id="onco12255-note-0011">
                      <p>Abbreviations: B, unstandardized coefficient; CI, confidence interval; FACT‐G, Functional Assessment of Cancer Therapy‐General; HADS, Hospital Anxiety and Depression Scale; SE, standard error.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>We also found an association between sarcopenia and HADS‐depression (Fig. <xref rid="onco12255-fig-0002" ref-type="fig">2</xref>). Patients with sarcopenia had higher rates of clinically significant depression symptoms (29.0% vs. 16.0%, <italic>p</italic> = .021). On multivariable linear regression, we found that sarcopenia was associated with higher HADS‐depression scores (B = 1.56, SE = 0.55, 95% CI = 0.47 to 2.65, <italic>p</italic> = .005). We did not find a significant association between sarcopenia and HADS‐anxiety (B = −0.04, SE = 0.55, 95% CI = −1.12 to 1.04, <italic>p</italic> = .943).</p>
                <fig fig-type="Figure" xml:lang="en" id="onco12255-fig-0002" orientation="portrait" position="float">
                  <label>Figure 2.</label>
                  <caption>
                    <p>Depression and anxiety among sarcopenic and nonsarcopenic patients.</p>
                    <p>Abbreviations: HADS, Hospital Anxiety and Depression Scale.</p>
                  </caption>
                  <graphic id="nlm-graphic-11" specific-use="sourcefile-name" xlink:href="onco12255-fig-0002">
                    <alt-text>image</alt-text>
                  </graphic>
                </fig>
              </sec>
            </sec>
            <sec id="onco12255-sec-0019">
              <title>Discussion</title>
              <p>In this exploratory analysis of patients with newly diagnosed, incurable lung and gastrointestinal cancer, we found that sarcopenia was associated with worse QOL and greater depression symptoms. Notably, patients in our sample were newly diagnosed, yet over half met criteria for sarcopenia on CT images acquired for routine clinical care. We also demonstrated a statistically significant relationship between the presence of sarcopenia and certain patient characteristics, such as age and sex. The remarkably high rates of sarcopenia in our sample, coupled with the negative impact of low muscle mass on patient outcomes in this population, underscore the critical need to address this issue early in the disease course for patients with advanced cancer.</p>
              <p>Our work highlights the considerably high prevalence of sarcopenia among patients with newly diagnosed, incurable cancer. Over half of patients met criteria for sarcopenia, which is higher than a prior study involving patients with lung and gastrointestinal cancer, and may be related to the fact that our study involved patients with advanced cancer, whereas the prior study included patients of all stages [<xref rid="onco12255-bib-0027" ref-type="ref">27</xref>]. A more comprehensive understanding of the frequency and impact of sarcopenia in this population can be instrumental in (a) identifying patients at risk for experiencing sarcopenia, (b) understanding how sarcopenia can influence patient outcomes, and (c) providing additional services to meet the supportive care needs of these patients. Additionally, by demonstrating the negative association between sarcopenia and patients’ QOL and mood soon after their cancer diagnosis, our work provides compelling evidence supporting the need for interventions, such as consultation with nutrition specialists or recommendations for exercise, to address sarcopenia and target patients earlier in their cancer course [<xref rid="onco12255-bib-0028" ref-type="ref">28</xref>], [<xref rid="onco12255-bib-0029" ref-type="ref">29</xref>], [<xref rid="onco12255-bib-0030" ref-type="ref">30</xref>], [<xref rid="onco12255-bib-0031" ref-type="ref">31</xref>]. Thus, our study successfully identifies the highly prevalent and problematic issue of sarcopenia in patients with newly diagnosed, incurable cancer, which can enable us to better support this population, improve the quality of their care, and enhance patient outcomes.</p>
              <p>To our knowledge, this is the first study to report that sarcopenia, assessed using CT scans collected as part of routine care, is associated with both QOL and depression symptoms in patients with newly diagnosed, incurable cancer. Researchers have postulated that the physical decline associated with sarcopenia reduces patients’ functional ability, which can adversely impact the QOL of patients with cancer [<xref rid="onco12255-bib-0032" ref-type="ref">32</xref>], [<xref rid="onco12255-bib-0033" ref-type="ref">33</xref>]. Similarly, the relationship between depressive symptoms and patients’ lack of appetite and diminished physical activity may provide a mechanism linking sarcopenia and depression among patients with cancer [<xref rid="onco12255-bib-0033" ref-type="ref">33</xref>], [<xref rid="onco12255-bib-0034" ref-type="ref">34</xref>], [<xref rid="onco12255-bib-0035" ref-type="ref">35</xref>], [<xref rid="onco12255-bib-0036" ref-type="ref">36</xref>]. Importantly, our findings will inform future efforts to address sarcopenia earlier in the cancer trajectory in order to improve outcomes for this highly symptomatic population [<xref rid="onco12255-bib-0019" ref-type="ref">19</xref>], [<xref rid="onco12255-bib-0037" ref-type="ref">37</xref>], [<xref rid="onco12255-bib-0038" ref-type="ref">38</xref>], [<xref rid="onco12255-bib-0039" ref-type="ref">39</xref>]. By evaluating patients with advanced cancer for the presence of sarcopenia at the time of diagnosis using routinely performed CT scans, we can identify those at higher risk for poor physical and emotional well‐being and begin to implement strategies to better meet the needs of these individuals.</p>
              <p>Notably, we identified patient characteristics associated with the presence of sarcopenia. We found that older patients were more likely to meet criteria for sarcopenia, a finding that aligns with the geriatric literature [<xref rid="onco12255-bib-0006" ref-type="ref">6</xref>], [<xref rid="onco12255-bib-0040" ref-type="ref">40</xref>], [<xref rid="onco12255-bib-0041" ref-type="ref">41</xref>]. Research suggests that older patients frequently experience diminished skeletal muscle mass and changes in muscle quality, thought to be related to neurologic, metabolic, hormonal, nutritional, and physical‐activity‐related factors [<xref rid="onco12255-bib-0041" ref-type="ref">41</xref>], [<xref rid="onco12255-bib-0042" ref-type="ref">42</xref>], [<xref rid="onco12255-bib-0043" ref-type="ref">43</xref>]. In turn, these changes in muscle mass and function can lead to disability, diminished mobility, functional dependence, and falls [<xref rid="onco12255-bib-0011" ref-type="ref">11</xref>], [<xref rid="onco12255-bib-0044" ref-type="ref">44</xref>], [<xref rid="onco12255-bib-0045" ref-type="ref">45</xref>]. Clinically, our findings support the need for oncologists to screen for sarcopenia in older adults with advanced cancer and address their nutritional and functional status early in the course of their care. We also found that female patients were less likely to have sarcopenia than males, consistent with previous work [<xref rid="onco12255-bib-0006" ref-type="ref">6</xref>], [<xref rid="onco12255-bib-0046" ref-type="ref">46</xref>], [<xref rid="onco12255-bib-0047" ref-type="ref">47</xref>]. A potential explanation is that the pattern of muscle loss may differ between male and female patients, as research has previously demonstrated [<xref rid="onco12255-bib-0048" ref-type="ref">48</xref>], [<xref rid="onco12255-bib-0049" ref-type="ref">49</xref>], [<xref rid="onco12255-bib-0050" ref-type="ref">50</xref>]. Moreover, another explanation may relate to the different sex‐specific cutoffs used to quantify sarcopenia, which although consistent with consensus guidelines, may differ in certain populations. In addition, we found that education beyond high school was associated with higher likelihood of sarcopenia. This finding is hypothesis‐generating, and additional research should seek to confirm and expand upon this result. Collectively, our findings help identify individuals at higher risk for having sarcopenia soon after the diagnosis of advanced cancer and should help inform future efforts to target these patients with interventions tailored to their needs.</p>
              <p>Several limitations of our study warrant consideration. First, we performed this study at a single academic cancer center in a patient sample with limited racial and ethnic diversity. Thus, our findings may not generalize to other, more heterogeneous populations, and additional research should seek to confirm our results in more diverse populations. Second, this study included patients who had enrolled in a randomized trial of early palliative care, and these patients may differ from those who choose not to participate in clinical trials. Also, by excluding patients already receiving palliative care services and those who needed immediate referral for palliative care or hospice, we may be underestimating the prevalence of sarcopenia, as these excluded patients may have had more advanced sarcopenia than those enrolled. Third, we did not collect information about whether patients utilized other services, such as physical and occupational therapy or dietary and nutrition services, which may affect patients’ ability to maintain muscle mass [<xref rid="onco12255-bib-0030" ref-type="ref">30</xref>], [<xref rid="onco12255-bib-0051" ref-type="ref">51</xref>], [<xref rid="onco12255-bib-0052" ref-type="ref">52</xref>], [<xref rid="onco12255-bib-0053" ref-type="ref">53</xref>]. Notably, participants are unlikely to have extensively received these services, as we conducted the study early in patients’ disease course. In addition, we lack information regarding weight loss for the participants in this study, and therefore cannot comment on how weight change influences sarcopenia and patient‐reported outcomes. Furthermore, although prior research has shown differential effects of sarcopenia on patient outcomes depending on patient BMI, we do not have the sample size for BMI‐specific subgroup analyses [<xref rid="onco12255-bib-0006" ref-type="ref">6</xref>], [<xref rid="onco12255-bib-0027" ref-type="ref">27</xref>]. Finally, the cross‐sectional nature of our study allows us only to report associations between sarcopenia and patients’ QOL and mood, and thus we cannot state the directionality of the relationships. In addition, without longitudinal data, our study does not provide information about how changes in muscle mass throughout the cancer trajectory may further influence patients’ QOL and mood.</p>
            </sec>
            <sec id="onco12255-sec-0020">
              <title>Conclusion</title>
              <p>In summary, we demonstrated that patients with newly diagnosed, incurable cancer experience high rates of sarcopenia assessed using CT scans performed as part of routine clinical care. It is noteworthy that patients with sarcopenia report worse QOL and greater depression symptoms, as this highlights an important need for interventions to address muscle loss early in the course of illness among patients with incurable cancer. Future research should focus on determining the optimal timing and modality of efforts to assess and treat sarcopenia while working to improve the QOL and mood outcomes of patients with advanced cancer.</p>
              <boxed-text position="float" orientation="portrait">
                <p>See <ext-link ext-link-type="uri" xlink:href="http://www.TheOncologist.com">http://www.TheOncologist.com</ext-link> for supplemental material available online.</p>
              </boxed-text>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material id="PMC_1" content-type="local-data">
                <caption>
                  <title>Supplemental Data</title>
                </caption>
                <media mimetype="text" mime-subtype="html" xlink:href="supp_23_1_97__index.html"/>
                <media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_the2017-0255_onco12255-sup-0001-suppinfo01.pdf"/>
                <media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_the2017-0255_onco12255-sup-0002-suppinfo02.pdf"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="onco12255-sec-0021">
              <title>Acknowledgments</title>
              <p>This study was supported by grants from the National Institute of Nursing Research (R01 NR012735) and the National Cancer Institute (K24 CA181253).</p>
            </ack>
            <fn-group>
              <fn id="onco12255-note-1001">
                <p><bold>For Further Reading:</bold> Hánah N. Rier, Agnes Jager, Stefan Sleijfer et al. The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature. <italic><bold>The Oncologist</bold></italic> 2016;21:1396‐1409.</p>
              </fn>
              <fn id="onco12255-note-1002">
                <p><bold>Implications for Practice:</bold> An increasing number of studies underline the clinical value of low muscle mass as a prognostic factor for adverse outcomes in cancer patients. However, studies show large heterogeneity because of the lack of a standardized approach to measure muscle mass and the lack of reference populations. As a result, the interpretation of data and further progress are severely hampered, hindering the implementation of muscle measurement in oncological care. This review summarizes the methods of diagnosing low muscle mass in cancer patients, the difference between underlying syndromes such as sarcopenia and cachexia, and the association with clinical outcomes described so far.</p>
              </fn>
            </fn-group>
            <sec id="onco12255-sec-0022" sec-type="con">
              <title>Author Contributions</title>
              <p><bold>Conception/design</bold>: Ryan D. Nipp, Georg Fuchs, Areej El‐Jawahri, Julia Mario, Fabian M. Troschel, Joseph A. Greer, Emily R. Gallagher, Vicki A. Jackson, Avinash Kambadakone, Theodore S. Hong, Jennifer S. Temel, Florian J. Fintelmann</p>
              <p><bold>Provision of study material or patients</bold>: Ryan D. Nipp, Georg Fuchs, Areej El‐Jawahri, Julia Mario, Fabian M. Troschel, Joseph A. Greer, Emily R. Gallagher, Vicki A. Jackson, Avinash Kambadakone, Theodore S. Hong, Jennifer S. Temel, Florian J. Fintelmann</p>
              <p><bold>Collection and/or assembly of data</bold>: Ryan D. Nipp, Georg Fuchs, Areej El‐Jawahri, Julia Mario, Fabian M. Troschel, Joseph A. Greer, Emily R. Gallagher, Vicki A. Jackson, Avinash Kambadakone, Theodore S. Hong, Jennifer S. Temel, Florian J. Fintelmann</p>
              <p><bold>Data analysis and interpretation</bold>: Ryan D. Nipp, Georg Fuchs, Areej El‐Jawahri, Julia Mario, Fabian M. Troschel, Joseph A. Greer, Emily R. Gallagher, Vicki A. Jackson, Avinash Kambadakone, Theodore S. Hong, Jennifer S. Temel, Florian J. Fintelmann</p>
              <p><bold>Manuscript writing</bold>: Ryan D. Nipp, Georg Fuchs, Areej El‐Jawahri, Julia Mario, Fabian M. Troschel, Joseph A. Greer, Emily R. Gallagher, Vicki A. Jackson, Avinash Kambadakone, Theodore S. Hong, Jennifer S. Temel, Florian J. Fintelmann</p>
              <p><bold>Final approval of manuscript</bold>: Ryan D. Nipp, Georg Fuchs, Areej El‐Jawahri, Julia Mario, Fabian M. Troschel, Joseph A. Greer, Emily R. Gallagher, Vicki A. Jackson, Avinash Kambadakone, Theodore S. Hong, Jennifer S. Temel, Florian J. Fintelmann</p>
            </sec>
            <sec id="onco12255-sec-0023" sec-type="disclosure">
              <title>Disclosures</title>
              <p>The authors indicated no financial relationships.</p>
            </sec>
            <ref-list content-type="cited-references">
              <title>References</title>
              <ref id="onco12255-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0001"><string-name><surname>Dewys</surname><given-names>WD</given-names></string-name>, 
<string-name><surname>Begg</surname><given-names>C</given-names></string-name>, 
<string-name><surname>Lavin</surname><given-names>PT</given-names></string-name> et al. <article-title>Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group</article-title>. <source>Am J Med</source>
<year>1980</year>;<volume>69</volume>:<fpage>491</fpage>–<lpage>497</lpage>.
<pub-id pub-id-type="pmid">7424938</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0002"><string-name><surname>Fearon</surname><given-names>KC.</given-names></string-name><article-title>Cancer cachexia: Developing multimodal therapy for a multidimensional problem</article-title>. <source>Eur J Cancer</source><year>2008</year>;<volume>44</volume>:<fpage>1124</fpage>–<lpage>1132</lpage>.
<pub-id pub-id-type="pmid">18375115</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0003"><string-name><surname>Shachar</surname><given-names>SS</given-names></string-name>, 
<string-name><surname>Deal</surname><given-names>AM</given-names></string-name>, 
<string-name><surname>Weinberg</surname><given-names>M</given-names></string-name> et al. <article-title>Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane‐based chemotherapy</article-title>. <source>Clin Cancer Res</source>
<year>2017</year>;<volume>23</volume>:<fpage>658</fpage>–<lpage>665</lpage>.
<pub-id pub-id-type="pmid">27489287</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0004"><string-name><surname>Shachar</surname><given-names>SS</given-names></string-name>, 
<string-name><surname>Williams</surname><given-names>GR</given-names></string-name>, 
<string-name><surname>Muss</surname><given-names>HB</given-names></string-name> et al. <article-title>Prognostic value of sarcopenia in adults with solid tumours: A meta‐analysis and systematic review</article-title>. <source>Eur J Cancer</source>
<year>2016</year>;<volume>57</volume>:<fpage>58</fpage>–<lpage>67</lpage>.
<pub-id pub-id-type="pmid">26882087</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0005"><string-name><surname>Del Fabbro</surname><given-names>E</given-names></string-name>, 
<string-name><surname>Parsons</surname><given-names>H</given-names></string-name>, 
<string-name><surname>Warneke</surname><given-names>CL</given-names></string-name> et al. <article-title>The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer</article-title>. <source>The Oncologist</source>
<year>2012</year>;<volume>17</volume>:<fpage>1240</fpage>–<lpage>1245</lpage>.
<pub-id pub-id-type="pmid">22903527</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0006"><string-name><surname>Prado</surname><given-names>CM</given-names></string-name>, 
<string-name><surname>Lieffers</surname><given-names>JR</given-names></string-name>, 
<string-name><surname>McCargar</surname><given-names>LJ</given-names></string-name> et al. <article-title>Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population‐based study</article-title>. <source>Lancet Oncol</source>
<year>2008</year>;<volume>9</volume>:<fpage>629</fpage>–<lpage>635</lpage>.
<pub-id pub-id-type="pmid">18539529</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0007"><string-name><surname>Tisdale</surname><given-names>MJ.</given-names></string-name><article-title>Mechanisms of cancer cachexia</article-title>. <source>Physiol Rev</source><year>2009</year>;<volume>89</volume>:<fpage>381</fpage>–<lpage>410</lpage>.
<pub-id pub-id-type="pmid">19342610</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0008"><string-name><surname>Mantovani</surname><given-names>G</given-names></string-name>, 
<string-name><surname>Macciò</surname><given-names>A</given-names></string-name>, 
<string-name><surname>Lai</surname><given-names>P</given-names></string-name> et al. <article-title>Cytokine activity in cancer‐related anorexia/cachexia: Role of megestrol acetate and medroxyprogesterone acetate</article-title>. <source>Semin Oncol</source>
<year>1998</year>;<volume>25</volume>(<issue>2 suppl 6</issue>):<fpage>45</fpage>–<lpage>52</lpage>.
<pub-id pub-id-type="pmid">9625383</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0009"><string-name><surname>Argilés</surname><given-names>JM</given-names></string-name>, 
<string-name><surname>Alvarez</surname><given-names>B</given-names></string-name>, 
<string-name><surname>López‐Soriano</surname><given-names>FJ.</given-names></string-name><article-title>The metabolic basis of cancer cachexia</article-title>. <source>Med Res Rev</source><year>1997</year>;<volume>17</volume>:<fpage>477</fpage>–<lpage>498</lpage>.
<pub-id pub-id-type="pmid">9276862</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0010"><string-name><surname>Gewandter</surname><given-names>JS</given-names></string-name>, 
<string-name><surname>Dale</surname><given-names>W</given-names></string-name>, 
<string-name><surname>Magnuson</surname><given-names>A</given-names></string-name> et al. <article-title>Associations between a patient‐reported outcome (PRO) measure of sarcopenia and falls, functional status, and physical performance in older patients with cancer</article-title>. <source>J Geriatr Oncol</source>
<year>2015</year>;<volume>6</volume>:<fpage>433</fpage>–<lpage>441</lpage>.
<pub-id pub-id-type="pmid">26365897</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0011"><string-name><surname>Janssen</surname><given-names>I</given-names></string-name>, 
<string-name><surname>Heymsfield</surname><given-names>SB</given-names></string-name>, 
<string-name><surname>Ross</surname><given-names>R.</given-names></string-name><article-title>Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability</article-title>. <source>J Am Geriatr Soc</source><year>2002</year>;<volume>50</volume>:<fpage>889</fpage>–<lpage>896</lpage>.
<pub-id pub-id-type="pmid">12028177</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0012"><string-name><surname>Velikova</surname><given-names>G</given-names></string-name>, 
<string-name><surname>Wright</surname><given-names>P</given-names></string-name>, 
<string-name><surname>Smith</surname><given-names>AB</given-names></string-name> et al. <article-title>Self‐reported quality of life of individual cancer patients: Concordance of results with disease course and medical records</article-title>. <source>J Clin Oncol</source>
<year>2001</year>;<volume>19</volume>:<fpage>2064</fpage>–<lpage>2073</lpage>.
<pub-id pub-id-type="pmid">11283140</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0013"><string-name><surname>Loprinzi</surname><given-names>CL.</given-names></string-name><article-title>Management of cancer anorexia/cachexia</article-title>. <source>Support Care Cancer</source><year>1995</year>;<volume>3</volume>:<fpage>120</fpage>–<lpage>122</lpage>.
<pub-id pub-id-type="pmid">7773579</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0014"><string-name><surname>Muscaritoli</surname><given-names>M</given-names></string-name>, 
<string-name><surname>Anker</surname><given-names>SD</given-names></string-name>, 
<string-name><surname>Argiles</surname><given-names>J</given-names></string-name> et al. <article-title>Consensus definition of sarcopenia, cachexia and pre‐cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia‐anorexia in chronic wasting diseases” and “nutrition in geriatrics.</article-title>” <source>Clin Nutr</source>
<year>2010</year>;<volume>29</volume>:<fpage>154</fpage>–<lpage>159</lpage>.
<pub-id pub-id-type="pmid">20060626</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0015"><string-name><surname>Fearon</surname><given-names>K</given-names></string-name>, 
<string-name><surname>Strasser</surname><given-names>F</given-names></string-name>, 
<string-name><surname>Anker</surname><given-names>SD</given-names></string-name> et al. <article-title>Definition and classification of cancer cachexia: An international consensus</article-title>. <source>Lancet Oncol</source>
<year>2011</year>;<volume>12</volume>:<fpage>489</fpage>–<lpage>495</lpage>.
<pub-id pub-id-type="pmid">21296615</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0016"><string-name><surname>Broughman</surname><given-names>JR</given-names></string-name>, 
<string-name><surname>Williams</surname><given-names>GR</given-names></string-name>, 
<string-name><surname>Deal</surname><given-names>AM</given-names></string-name> et al. <article-title>Prevalence of sarcopenia in older patients with colorectal cancer</article-title>. <source>J Geriatr Oncol</source>
<year>2015</year>;<volume>6</volume>:<fpage>442</fpage>–<lpage>445</lpage>.
<pub-id pub-id-type="pmid">26365898</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0017"><string-name><surname>Heymsfield</surname><given-names>SB</given-names></string-name>, 
<string-name><surname>McManus</surname><given-names>CB.</given-names></string-name><article-title>Tissue components of weight loss in cancer patients: A new method of study and preliminary observations</article-title>. <source>Cancer</source><year>1985</year>;<volume>55</volume>(<issue>1 suppl</issue>):<fpage>238</fpage>–<lpage>249</lpage>.
<pub-id pub-id-type="pmid">3965090</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0018"><string-name><surname>Thoresen</surname><given-names>L</given-names></string-name>, 
<string-name><surname>Frykholm</surname><given-names>G</given-names></string-name>, 
<string-name><surname>Lydersen</surname><given-names>S</given-names></string-name> et al. <article-title>Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results</article-title>. <source>Clin Nutr</source>
<year>2013</year>;<volume>32</volume>:<fpage>65</fpage>–<lpage>72</lpage>.
<pub-id pub-id-type="pmid">22695408</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0019"><string-name><surname>Teunissen</surname><given-names>SC</given-names></string-name>, 
<string-name><surname>Wesker</surname><given-names>W</given-names></string-name>, 
<string-name><surname>Kruitwagen</surname><given-names>C</given-names></string-name> et al. <article-title>Symptom prevalence in patients with incurable cancer: A systematic review</article-title>. <source>J Pain Symptom Manage</source>
<year>2007</year>;<volume>34</volume>:<fpage>94</fpage>–<lpage>104</lpage>.
<pub-id pub-id-type="pmid">17509812</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0020"><string-name><surname>Davis</surname><given-names>MP</given-names></string-name>, 
<string-name><surname>Dreicer</surname><given-names>R</given-names></string-name>, 
<string-name><surname>Walsh</surname><given-names>D</given-names></string-name> et al. <article-title>Appetite and cancer‐associated anorexia: A review</article-title>. <source>J Clin Oncol</source>
<year>2004</year>;<volume>22</volume>:<fpage>1510</fpage>–<lpage>1517</lpage>.
<pub-id pub-id-type="pmid">15084624</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0021"><string-name><surname>Temel</surname><given-names>JS</given-names></string-name>, 
<string-name><surname>Greer</surname><given-names>JA</given-names></string-name>, 
<string-name><surname>El‐Jawahri</surname><given-names>A</given-names></string-name> et al. <article-title>Effects of early integrated palliative care in patients with lung and GI cancer: A randomized clinical trial</article-title>. <source>J Clin Oncol</source>
<year>2017</year>;<volume>35</volume>:<fpage>834</fpage>–<lpage>841</lpage>.
<pub-id pub-id-type="pmid">28029308</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0022"><string-name><surname>Cella</surname><given-names>DF</given-names></string-name>, 
<string-name><surname>Tulsky</surname><given-names>DS</given-names></string-name>, 
<string-name><surname>Gray</surname><given-names>G</given-names></string-name> et al. <article-title>The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure</article-title>. <source>J Clin Oncol</source>
<year>1993</year>;<volume>11</volume>:<fpage>570</fpage>–<lpage>579</lpage>.
<pub-id pub-id-type="pmid">8445433</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0023"><string-name><surname>Zigmond</surname><given-names>AS</given-names></string-name>, 
<string-name><surname>Snaith</surname><given-names>RP.</given-names></string-name><article-title>The hospital anxiety and depression scale</article-title>. <source>Acta Psychiatr Scand</source><year>1983</year>;<volume>67</volume>:<fpage>361</fpage>–<lpage>370</lpage>.
<pub-id pub-id-type="pmid">6880820</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0024"><string-name><surname>Mitsiopoulos</surname><given-names>N</given-names></string-name>, 
<string-name><surname>Baumgartner</surname><given-names>RN</given-names></string-name>, 
<string-name><surname>Heymsfield</surname><given-names>SB</given-names></string-name> et al. <article-title>Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography</article-title>. <source>J Appl Physiol (1985).</source>
<year>1998</year>;<volume>85</volume>:<fpage>115</fpage>–<lpage>122</lpage>.
<pub-id pub-id-type="pmid">9655763</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0025"><string-name><surname>Parker</surname><given-names>PA</given-names></string-name>, 
<string-name><surname>Baile</surname><given-names>WF</given-names></string-name>, 
<string-name><surname>de Moor</surname><given-names>C</given-names></string-name> et al. <article-title>Psychosocial and demographic predictors of quality of life in a large sample of cancer patients</article-title>. <source>Psychooncology</source>
<year>2003</year>;<volume>12</volume>:<fpage>183</fpage>–<lpage>193</lpage>.
<pub-id pub-id-type="pmid">12619150</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0026"><string-name><surname>Nipp</surname><given-names>RD</given-names></string-name>, 
<string-name><surname>Greer</surname><given-names>JA</given-names></string-name>, 
<string-name><surname>Traeger</surname><given-names>L</given-names></string-name> et al. <article-title>Which patients experience improved quality of life (QOL) and mood from early palliative care (PC)?</article-title>
<source>J Clin Oncol</source>
<year>2014</year>;<volume>32</volume>,(<issue>suppl 31</issue>):16a.
</mixed-citation>
              </ref>
              <ref id="onco12255-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0027"><string-name><surname>Martin</surname><given-names>L</given-names></string-name>, 
<string-name><surname>Birdsell</surname><given-names>L</given-names></string-name>, 
<string-name><surname>Macdonald</surname><given-names>N</given-names></string-name> et al. <article-title>Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index</article-title>. <source>J Clin Oncol</source>
<year>2013</year>;<volume>31</volume>:<fpage>1539</fpage>–<lpage>1547</lpage>.
<pub-id pub-id-type="pmid">23530101</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0028"><string-name><surname>Baldwin</surname><given-names>C</given-names></string-name>, 
<string-name><surname>Spiro</surname><given-names>A</given-names></string-name>, 
<string-name><surname>Ahern</surname><given-names>R</given-names></string-name> et al. <article-title>Oral nutritional interventions in malnourished patients with cancer: A systematic review and meta‐analysis</article-title>. <source>J Natl Cancer Inst</source>
<year>2012</year>;<volume>104</volume>:<fpage>371</fpage>–<lpage>385</lpage>.
<pub-id pub-id-type="pmid">22345712</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0029"><string-name><surname>Galvão</surname><given-names>DA</given-names></string-name>, 
<string-name><surname>Taaffe</surname><given-names>DR</given-names></string-name>, 
<string-name><surname>Spry</surname><given-names>N</given-names></string-name> et al. <article-title>Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: A randomized controlled trial</article-title>. <source>J Clin Oncol</source>
<year>2010</year>;<volume>28</volume>:<fpage>340</fpage>–<lpage>347</lpage>.
<pub-id pub-id-type="pmid">19949016</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0030"><string-name><surname>Segal</surname><given-names>RJ</given-names></string-name>, 
<string-name><surname>Reid</surname><given-names>RD</given-names></string-name>, 
<string-name><surname>Courneya</surname><given-names>KS</given-names></string-name> et al. <article-title>Resistance exercise in men receiving androgen deprivation therapy for prostate cancer</article-title>. <source>J Clin Oncol</source>
<year>2003</year>;<volume>21</volume>:<fpage>1653</fpage>–<lpage>1659</lpage>.
<pub-id pub-id-type="pmid">12721238</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0031"><string-name><surname>Courneya</surname><given-names>KS</given-names></string-name>, 
<string-name><surname>Segal</surname><given-names>RJ</given-names></string-name>, 
<string-name><surname>Mackey</surname><given-names>JR</given-names></string-name> et al. <article-title>Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: A multicenter randomized controlled trial</article-title>. <source>J Clin Oncol</source>
<year>2007</year>;<volume>25</volume>:<fpage>4396</fpage>–<lpage>4404</lpage>.
<pub-id pub-id-type="pmid">17785708</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0032"><string-name><surname>Keogh</surname><given-names>JW</given-names></string-name>, 
<string-name><surname>MacLeod</surname><given-names>RD.</given-names></string-name><article-title>Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: A systematic review</article-title>. <source>J Pain Symptom Manage</source><year>2012</year>;<volume>43</volume>:<fpage>96</fpage>–<lpage>110</lpage>.
<pub-id pub-id-type="pmid">21640547</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0033"><string-name><surname>Illman</surname><given-names>J</given-names></string-name>, 
<string-name><surname>Corringham</surname><given-names>R</given-names></string-name>, 
<string-name><surname>Robinson</surname><given-names>D</given-names><suffix>Jr</suffix></string-name>. et al. <article-title>Are inflammatory cytokines the common link between cancer‐associated cachexia and depression?</article-title><source>J Support Oncol</source><year>2005</year>;<volume>3</volume>:<fpage>37</fpage>–<lpage>50</lpage>.
<pub-id pub-id-type="pmid">15724944</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0034"><string-name><surname>Bukberg</surname><given-names>J</given-names></string-name>, 
<string-name><surname>Penman</surname><given-names>D</given-names></string-name>, 
<string-name><surname>Holland</surname><given-names>JC.</given-names></string-name><article-title>Depression in hospitalized cancer patients</article-title>. <source>Psychosom Med</source><year>1984</year>;<volume>46</volume>:<fpage>199</fpage>–<lpage>212</lpage>.
<pub-id pub-id-type="pmid">6739680</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0035"><string-name><surname>Jeejeebhoy</surname><given-names>KN.</given-names></string-name><article-title>Malnutrition, fatigue, frailty, vulnerability, sarcopenia and cachexia: Overlap of</article-title><source>clinical features. Curr Opin Clin Nutr Metab Care</source><year>2012</year>;<volume>15</volume>:<fpage>213</fpage>–<lpage>219</lpage>.
<pub-id pub-id-type="pmid">22450775</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0036"><string-name><surname>Dy</surname><given-names>SM</given-names></string-name>, 
<string-name><surname>Lorenz</surname><given-names>KA</given-names></string-name>, 
<string-name><surname>Naeim</surname><given-names>A</given-names></string-name> et al. <article-title>Evidence‐based recommendations for cancer fatigue, anorexia, depression, and dyspnea</article-title>. <source>J Clin Oncol</source>
<year>2008</year>;<volume>26</volume>:<fpage>3886</fpage>–<lpage>3895</lpage>.
<pub-id pub-id-type="pmid">18688057</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0037"><string-name><surname>Miovic</surname><given-names>M</given-names></string-name>, 
<string-name><surname>Block</surname><given-names>S.</given-names></string-name><article-title>Psychiatric disorders in advanced cancer</article-title>. <source>Cancer</source><year>2007</year>;<volume>110</volume>:<fpage>1665</fpage>–<lpage>1676</lpage>.
<pub-id pub-id-type="pmid">17847017</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0038"><string-name><surname>Lutz</surname><given-names>S</given-names></string-name>, 
<string-name><surname>Norrell</surname><given-names>R</given-names></string-name>, 
<string-name><surname>Bertucio</surname><given-names>C</given-names></string-name> et al. <article-title>Symptom frequency and severity in patients with metastatic or locally recurrent lung cancer: A prospective study using the Lung Cancer Symptom Scale in a community hospital</article-title>. <source>J Palliat Med</source>
<year>2001</year>;<volume>4</volume>:<fpage>157</fpage>–<lpage>165</lpage>.
<pub-id pub-id-type="pmid">11441624</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0039"><string-name><surname>Chang</surname><given-names>VT</given-names></string-name>, 
<string-name><surname>Hwang</surname><given-names>SS</given-names></string-name>, 
<string-name><surname>Feuerman</surname><given-names>M</given-names></string-name> et al. <article-title>Symptom and quality of life survey of medical oncology patients at a Veterans Affairs medical center: A role for symptom assessment</article-title>. <source>Cancer</source>
<year>2000</year>;<volume>88</volume>:<fpage>1175</fpage>–<lpage>1183</lpage>.
<pub-id pub-id-type="pmid">10699909</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0040"><string-name><surname>Cruz‐Jentoft</surname><given-names>AJ</given-names></string-name>, 
<string-name><surname>Landi</surname><given-names>F</given-names></string-name>, 
<string-name><surname>Topinková</surname><given-names>E</given-names></string-name> et al. <article-title>Understanding sarcopenia as a geriatric syndrome</article-title>. <source>Curr Opin Clin Nutr Metab Care</source>
<year>2010</year>;<volume>13</volume>:<fpage>1</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="pmid">19915458</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0041">
                <label>41</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0041"><string-name><surname>Doherty</surname><given-names>TJ.</given-names></string-name><article-title>Invited review: Aging and sarcopenia</article-title>. <source>J Appl Physiol (1985)</source><year>2003</year>;<volume>95</volume>:<fpage>1717</fpage>–<lpage>1727</lpage>.
<pub-id pub-id-type="pmid">12970377</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0042">
                <label>42</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0042"><string-name><surname>Roubenoff</surname><given-names>R</given-names></string-name>, 
<string-name><surname>Hughes</surname><given-names>VA.</given-names></string-name><article-title>Sarcopenia: Current concepts</article-title>. <source>J Gerontol A Biol Sci Med Sci</source><year>2000</year>;<volume>55</volume>:<fpage>M716</fpage>–<lpage>M724</lpage>.
<pub-id pub-id-type="pmid">11129393</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0043">
                <label>43</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0043"><string-name><surname>Welle</surname><given-names>S.</given-names></string-name><article-title>Cellular and molecular basis of age‐related sarcopenia</article-title>. <source>Can J Appl Physiol.</source><year>2002</year>;<volume>27</volume>:<fpage>19</fpage>–<lpage>41</lpage>.
<pub-id pub-id-type="pmid">11880689</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0044">
                <label>44</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0044"><string-name><surname>Lauretani</surname><given-names>F</given-names></string-name>, 
<string-name><surname>Russo</surname><given-names>CR</given-names></string-name>, 
<string-name><surname>Bandinelli</surname><given-names>S</given-names></string-name> et al. <article-title>Age‐associated changes in skeletal muscles and their effect on mobility: An operational diagnosis of sarcopenia</article-title>. <source>J Appl Physiol</source> (1985) <year>2003</year>;<volume>95</volume>:<fpage>1851</fpage>–<lpage>1860</lpage>.
<pub-id pub-id-type="pmid">14555665</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0045">
                <label>45</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0045"><string-name><surname>Landi</surname><given-names>F</given-names></string-name>, 
<string-name><surname>Liperoti</surname><given-names>R</given-names></string-name>, 
<string-name><surname>Russo</surname><given-names>A</given-names></string-name> et al. <article-title>Sarcopenia as a risk factor for falls in elderly individuals: Results from the ilSIRENTE study</article-title>. <source>Clin Nutr</source>
<year>2012</year>;<volume>31</volume>:<fpage>652</fpage>–<lpage>658</lpage>.
<pub-id pub-id-type="pmid">22414775</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0046">
                <label>46</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0046"><string-name><surname>Barret</surname><given-names>M</given-names></string-name>, 
<string-name><surname>Antoun</surname><given-names>S</given-names></string-name>, 
<string-name><surname>Dalban</surname><given-names>C</given-names></string-name> et al. <article-title>Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer</article-title>. <source>Nutr Cancer</source>
<year>2014</year>;<volume>66</volume>:<fpage>583</fpage>–<lpage>589</lpage>.
<pub-id pub-id-type="pmid">24707897</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0047">
                <label>47</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0047"><string-name><surname>Morishita</surname><given-names>S</given-names></string-name>, 
<string-name><surname>Kaida</surname><given-names>K</given-names></string-name>, 
<string-name><surname>Tanaka</surname><given-names>T</given-names></string-name> et al. <article-title>Prevalence of sarcopenia and relevance of body composition, physiological function, fatigue, and health‐related quality of life in patients before allogeneic hematopoietic stem cell transplantation</article-title>. <source>Support Care Cancer</source>
<year>2012</year>;<volume>20</volume>:<fpage>3161</fpage>–<lpage>3168</lpage>.
<pub-id pub-id-type="pmid">22526152</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0048">
                <label>48</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0048"><string-name><surname>Melton</surname><given-names>LJ</given-names></string-name> 3rd, 
<string-name><surname>Khosla</surname><given-names>S</given-names></string-name>, 
<string-name><surname>Crowson</surname><given-names>CS</given-names></string-name> et al. <article-title>Epidemiology of sarcopenia</article-title>. <source>J Am Geriatr Soc</source>
<year>2000</year>;<volume>48</volume>:<fpage>625</fpage>–<lpage>630</lpage>.
<pub-id pub-id-type="pmid">10855597</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0049">
                <label>49</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0049"><string-name><surname>Janssen</surname><given-names>I</given-names></string-name>, 
<string-name><surname>Heymsfield</surname><given-names>SB</given-names></string-name>, 
<string-name><surname>Wang</surname><given-names>ZM</given-names></string-name> et al. <article-title>Skeletal muscle mass and distribution in 468 men and women aged 18–88 yr</article-title>. <source>J Appl Physiol (1985)</source>
<year>2000</year>;<volume>89</volume>:<fpage>81</fpage>–<lpage>88</lpage>.
<pub-id pub-id-type="pmid">10904038</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0050">
                <label>50</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0050"><string-name><surname>Goodpaster</surname><given-names>BH</given-names></string-name>, 
<string-name><surname>Park</surname><given-names>SW</given-names></string-name>, 
<string-name><surname>Harris</surname><given-names>TB</given-names></string-name> et al. <article-title>The loss of skeletal muscle strength, mass, and quality in older adults: The health, aging and body composition study</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>
<year>2006</year>;<volume>61</volume>:<fpage>1059</fpage>–<lpage>1064</lpage>.
<pub-id pub-id-type="pmid">17077199</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0051">
                <label>51</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0051"><string-name><surname>Bauer</surname><given-names>JD</given-names></string-name>, 
<string-name><surname>Capra</surname><given-names>S.</given-names></string-name><article-title>Nutrition intervention improves outcomes in patients with cancer cachexia receiving chemotherapy: A pilot study</article-title>. <source>Support Care Cancer</source><year>2005</year>;<volume>13</volume>:<fpage>270</fpage>–<lpage>274</lpage>.
<pub-id pub-id-type="pmid">15583950</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0052">
                <label>52</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0052"><string-name><surname>Mello</surname><given-names>M</given-names></string-name>, 
<string-name><surname>Tanaka</surname><given-names>C</given-names></string-name>, 
<string-name><surname>Dulley</surname><given-names>FL.</given-names></string-name><article-title>Effects of an exercise program on muscle performance in patients undergoing allogeneic bone marrow transplantation</article-title>. <source>Bone Marrow Transplant</source><year>2003</year>;<volume>32</volume>:<fpage>723</fpage>–<lpage>728</lpage>.
<pub-id pub-id-type="pmid">13130321</pub-id></mixed-citation>
              </ref>
              <ref id="onco12255-bib-0053">
                <label>53</label>
                <mixed-citation publication-type="journal" id="onco12255-cit-0053"><string-name><surname>Pergolotti</surname><given-names>M</given-names></string-name>, 
<string-name><surname>Williams</surname><given-names>GR</given-names></string-name>, 
<string-name><surname>Campbell</surname><given-names>C</given-names></string-name> et al. <article-title>Occupational therapy for adults with cancer: Why it matters</article-title>. <source>The Oncologist</source>
<year>2016</year>;<volume>21</volume>:<fpage>314</fpage>–<lpage>319</lpage>.
<pub-id pub-id-type="pmid">26865588</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
